STOCK TITAN

Arcturus Therape - ARCT STOCK NEWS

Welcome to our dedicated page for Arcturus Therape news (Ticker: ARCT), a resource for investors and traders seeking the latest updates and insights on Arcturus Therape stock.

Arcturus Therapeutics Holdings Inc. (ARCT) is a clinical-stage RNA medicines company pioneering novel therapeutics and vaccines through its proprietary delivery platforms. This news hub provides investors and researchers with timely updates on the company's progress in developing self-amplifying mRNA (sa-mRNA) vaccines and rare disease treatments.

Access official press releases covering regulatory milestones, clinical trial developments, and strategic partnerships. Our curated collection includes updates on the LUNAR® delivery system's applications, STARR® mRNA technology advancements, and global collaborations like the ARCALIS joint venture in Japan.

Key updates include earnings reports, research publications, manufacturing expansions, and patent grants. Bookmark this page for direct access to primary source materials about ARCT's work in nucleic acid therapeutics, including programs targeting liver disorders, respiratory diseases, and infectious disease prevention.

For stakeholders tracking RNA medicine innovation, this repository offers organized chronological updates without promotional commentary. Check regularly for verified information about clinical-stage candidates and technology licensing agreements that demonstrate Arcturus' position in the biotechnology sector.

Rhea-AI Summary

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) has selected ARCT-032, an aerosolized mRNA therapeutic candidate, for Cystic Fibrosis (CF) treatment. This candidate aims to express functional CFTR protein in the lungs, addressing the root cause of CF lung disease. The development is backed by preclinical data showing potential to restore CFTR activity in affected models. The company emphasizes ARCT-032's capability to benefit all CF patients, regardless of genetic mutations, enhancing existing treatment options.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.27%
Tags
none
-
Rhea-AI Summary

Arcturus Therapeutics Holdings announced approval from the Singapore Health Sciences Authority to conduct a Phase 2 clinical study for its COVID-19 vaccine candidate, ARCT-021. This follows promising results from the Phase 1/2 trial, which demonstrated a robust immune response in all participants. The Phase 2 study aims to identify the best vaccination regimen ahead of a global Phase 3 study anticipated in Q2 2021. Preliminary preclinical data indicated significant protection from SARS-CoV-2 in animal models, further supporting the candidate's potential efficacy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-54.17%
Tags
-
Rhea-AI Summary

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) has announced a public offering of 1,365,000 shares priced at $110.00 each, aiming for approximately $150 million in gross proceeds. The offering includes a 30-day option for underwriters to purchase an additional 204,750 shares. The funds are designated for clinical trials and manufacturing its LUNAR-COV19 vaccine. The offering is underpinned by a registration statement filed with the SEC, with closing anticipated around December 10, 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.07%
Tags
Rhea-AI Summary

Arcturus Therapeutics Holdings (NASDAQ: ARCT) announced plans for an underwritten public offering of its common stock, with all shares to be sold by the Company. Subject to market conditions, the offering includes a potential 15% overallotment option for underwriters. Proceeds will fund clinical trials and manufacturing of the LUNAR-COV19 vaccine candidate. The offering is registered under an effective SEC shelf, with a prospectus to follow. Piper Sandler & Co. and Guggenheim Securities are joint bookrunners.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.07%
Tags
-
Rhea-AI Summary

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) has commenced dosing in its Phase 1b clinical trial of ARCT-810 for Ornithine Transcarbamylase (OTC) deficiency, a rare and serious disorder. The study, involving 12 patients, will assess safety, tolerability, and pharmacokinetics at doses ranging from 0.2 mg/kg to 0.4 mg/kg. Previous studies indicated ARCT-810 was safe and well tolerated in healthy subjects, showing a favorable pharmacokinetic profile. OTC deficiency, affecting around 10,000 people worldwide, currently lacks FDA-approved treatments. Arcturus aims to leverage its mRNA platform to address this unmet medical need.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.4%
Tags
none
-
Rhea-AI Summary

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced its participation in Piper Sandler’s 32nd Annual Virtual Healthcare Conference, scheduled for December 1, 2020, at 10:00 a.m. ET. The company will present on The Road Ahead for COVID-19 Vaccines. Founded in 2013 and based in San Diego, Arcturus focuses on mRNA medicines and vaccines, including programs targeting COVID-19 and other diseases. The company has developed significant partnerships and holds a robust patent portfolio of 200 patents worldwide, aimed at advancing RNA therapeutic technologies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.24%
Tags
conferences
Rhea-AI Summary

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) reported its financial results for Q3 2020, with revenues of $2.3 million, a decrease from $3.3 million in Q3 2019. Operating expenses surged to $23.3 million, primarily due to increased spending on clinical trials for ARCT-021 and ARCT-810, leading to a net loss of $21.0 million, or $0.92 per share. Despite the losses, the company’s cash position improved to $307.1 million, bolstered by equity offerings. The ARCT-021 COVID-19 vaccine candidate shows promising preliminary results, and the ARCT-810 candidate for OTC deficiency is advancing into further studies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.78%
Tags
-
Rhea-AI Summary

Arcturus Therapeutics (Nasdaq: ARCT) reported positive interim results from its Phase 1/2 study of ARCT-021, a COVID-19 vaccine candidate. Conducted in Singapore, the trial enrolled 106 subjects, revealing robust anti-spike protein IgG immune responses across multiple doses. The vaccine was well tolerated, showing a favorable safety profile. Additionally, Arcturus secured a financial commitment of up to $220 million from Singapore's Economic Development Board (EDB) to support vaccine manufacturing, including a $45 million loan linked to future sales.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-45.38%
Tags
-
Rhea-AI Summary

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) has announced its participation in several upcoming investor and scientific conferences. The company will present at the International mRNA Health Conference on November 10, 2020, at 1:40 p.m. ET, and at the Stifel Healthcare Conference on November 17, 2020, at 3:20 p.m. ET. Additionally, Arcturus will engage in a fireside chat at the Piper Sandler Healthcare Conference on November 23, 2020, at 10:00 a.m. ET. The company focuses on mRNA medicines and vaccines for infectious diseases and rare diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.85%
Tags
conferences
Rhea-AI Summary

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) will release its financial results for the quarter and nine months ended September 30, 2020, after market close on November 9, 2020. A conference call and webcast will be held at 4:30 PM ET on the same day to discuss the results and provide a corporate overview. The company specializes in mRNA medicines, focusing on vaccines for infectious diseases and rare diseases of the liver and respiratory system. Founded in 2013, Arcturus has developed a pipeline that includes self-replicating mRNA vaccine candidates for COVID-19 and influenza.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
conferences earnings
Arcturus Therape

Nasdaq:ARCT

ARCT Rankings

ARCT Stock Data

298.32M
24.83M
8.45%
92.53%
15.52%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO